CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04237207
NCT04237207N/ACompleted
CompareCT.gov

Evaluation of AutoSense OS on a Cochlear Implant Sound Processor Programmed With Target CI Fitting Software in Adult Users of the HiResolution Bionic Ear System

Advanced Bionics·interventional·Posted Jan 23, 2020·Updated May 13, 2022

In Brief

A clinical study evaluating Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software and 301-M062 sound processor & software for Hearing Loss and 3 related conditions. Completed, enrolled 22 participants across 6 sites.

Detailed Summary

This is a prospective within-subjects repeated-measures study that will enroll 24 adult users implanted with a HiResolution Bionic Ear System (HiRes 90K or newer). Subjects will be assigned to one of two cohorts based on audiometric results at the Baseline visit

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss, Ear Diseases, Hearing Disorders, Otorhinolaryngologic Diseases
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJan 23, 2020
Enrollment StartDec 17, 2019
Primary CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.4 years ago

Interventions

Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & softwaredevice

Control cochlear implant sound processor

301-M062 sound processor & softwaredevice

New cochlear implant sound processor